{"id":"f7fe8c92-0d90-52c9-984e-ada4529490fc","stable_key":"6660bba2-4fa0-590a-bf52-9803a24bea9f:osa-cpap-null","predicate":"no_detected_change_in_recorded_experiment","statement":"CPAP use was not adversely affected during the twelve-week modafinil OSA trial; longer-term adherence mediation remains untested here.","claim_class":"observational","status":"source_recorded","evidence_grade":"ungraded","direction":"neutral","is_public":true,"mechanism_event_id":"0e03efec-131f-5b6d-982a-82cefb31bd89","mechanism_event_label":"CPAP use was not adversely affected during the twelve-week modafinil OSA trial; longer-term adherence mediation remains untested here.","subject":{"id":"624e6a4b-f96d-5d12-8206-30d1e1715c26","slug":"modafinil","display_name":"Modafinil","entity_type_key":"drug"},"object":{"id":"96cbd640-0f31-55e7-9faa-1f8cee8bbc26","slug":"human-cpap-use","display_name":"Human CPAP use","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"0e03efec-131f-5b6d-982a-82cefb31bd89","stable_key":"6660bba2-4fa0-590a-bf52-9803a24bea9f:osa-cpap-null-event","event_type":"experimental_observation","label":"CPAP use was not adversely affected during the twelve-week modafinil OSA trial; longer-term adherence mediation remains untested here.","description":"For OSA, a 12-week randomized trial showed improved residual sleepiness and functioning in CPAP-treated patients and no adverse effect on CPAP use during that study. This is genuine symptomatic benefit; it does not show correction of airway obstruction or prevention of long-term vascular events. [OSA trial](https://pubmed.ncbi.nlm.nih.gov/16171291/)","status":"provisional","compartment":null,"participants":[{"entity":{"id":"624e6a4b-f96d-5d12-8206-30d1e1715c26","slug":"modafinil","display_name":"Modafinil","entity_type_key":"drug"},"role":"tested factor","stoichiometry":null,"state_label":"Adjunct modafinil","sequence_order":0,"notes":""},{"entity":{"id":"96cbd640-0f31-55e7-9faa-1f8cee8bbc26","slug":"human-cpap-use","display_name":"Human CPAP use","entity_type_key":"cellular_process"},"role":"measured outcome","stoichiometry":null,"state_label":"no_detected_change","sequence_order":1,"notes":""}]},"contexts":[{"dimension":"evidence_access","value_text":"Primary indexed abstract checked; full methods and figures not comprehensively reviewed.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_contrast","value_text":"{\"intervention\": \"Adjunct modafinil\", \"comparator\": \"Placebo adjunct\", \"endpoint\": \"CPAP use was not adversely affected during the twelve-week modafinil OSA trial; longer-term adherence mediation remains untested here.\", \"effect_direction\": \"no_detected_change\", \"combination\": \"single\", \"conditions\": []}","comparator":null,"unit":null,"notes":"Explicit extracted experimental comparison; source-derived draft.","entity":null},{"dimension":"experimental_model","value_text":"CPAP-treated OSA, human randomized trial.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"interpretation_status","value_text":"Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Interpret only within the recorded preparation, exposure and comparator. The complete source passage retains qualifications; unspecified doses/timing have not been extracted here. No clinical efficacy, nutrient deficiency or unique molecular mediation is inferred.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"CPAP use was not adversely affected during the twelve-week modafinil OSA trial; longer-term adherence mediation remains untested here.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Modafinil for treatment of residual excessive sleepiness in nasal continuous positive airway pressure-treated obstructive sleep apnea/hypopnea syndrome. | 2005 | DOI 10.1093/sleep/28.4.464 | PMID 16171291 | https://pubmed.ncbi.nlm.nih.gov/16171291/","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"source_locator","value_text":"Reviewed reference lines 170-170; exact primary location described in quoted passage where extracted.","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"f3c2fd52-1bff-5b23-817c-f74e7b4a2b9e","evidence_kind":"source_excerpt","locator":"Lines 170-170","start_line":170,"end_line":170,"excerpt":"For OSA, a 12-week randomized trial showed improved residual sleepiness and functioning in CPAP-treated patients and no adverse effect on CPAP use during that study. This is genuine symptomatic benefit; it does not show correction of airway obstruction or prevention of long-term vascular events. [OSA trial](https://pubmed.ncbi.nlm.nih.gov/16171291/)","model_system":"CPAP-treated OSA, human randomized trial.","directness":"reported_statement","verification_status":"source_recorded","notes":"Exact excerpt of the retained AI-assisted reviewed reference; primary sources are cited in primary_references and access scope is retained. Not a verbatim quotation from a primary paper.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"17a64928-eaa2-5117-ba4f-52dcbdf9cc9e","stable_key":"import-6660bba2-4fa0-590a-bf52-9803a24bea9f","title":"Modafinil: detailed mechanisms of action (reviewed 3 October 2026)","document_type":"imported_text","citation_label":"Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication.","file_path":"","sha256":"006008cb4cfd183dd3b0846d3abc66c8ebf40cf1b6bd1f0bcdb4f4d937a8e115","revision_id":"c85b3e2e-c18a-59fc-9e79-5c375e64d119","review_status":"source_recorded","notes":""}}],"relations":[{"id":"3330255e-071c-5e3d-ab50-91d9d62133bd","relation_type":"qualifies","notes":"Symptom benefit and contemporaneous CPAP use were measured separately; long-term vascular benefit or adherence harm is not established.","source_claim_id":"f7fe8c92-0d90-52c9-984e-ada4529490fc","source_claim_key":"6660bba2-4fa0-590a-bf52-9803a24bea9f:osa-cpap-null","source_statement":"CPAP use was not adversely affected during the twelve-week modafinil OSA trial; longer-term adherence mediation remains untested here.","target_claim_id":"81dbc706-2ac6-5440-8723-fe005bb54d1a","target_claim_key":"6660bba2-4fa0-590a-bf52-9803a24bea9f:osa-symptom","target_statement":"Modafinil improved residual sleepiness and functioning in a twelve-week trial of CPAP-treated OSA patients; it did not establish correction of airway obstruction."}],"conflicts":[],"corrections":[],"research":null}